Mirati Therapeutics (NASDAQ:MRTX) Market Perform Rating Reiterated Today By Leerink Swann; The Target Price Given is $9

September 17, 2017 - By Migdalia James

 Mirati Therapeutics (NASDAQ:MRTX) Market Perform Rating Reiterated Today By Leerink Swann; The Target Price Given is $9

Investors sentiment decreased to 0.81 in Q4 2016. Its down 0.23, from 1.04 in 2016Q3. It turned negative, as 12 investors sold Mirati Therapeutics, Inc. shares while 19 reduced holdings. 7 funds opened positions while 18 raised stakes. 9.10 million shares or 3.41% less from 9.42 million shares in 2016Q3 were reported.

Jpmorgan Chase And holds 0% or 54,261 shares. Rhenman And Prtnrs Asset Mgmt Ab stated it has 0.05% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Baker Bros Advisors L P reported 2.27 million shares. Morgan Stanley owns 69,101 shares for 0% of their portfolio. Citigroup has 200 shares for 0% of their portfolio. Macquarie Group stated it has 80,000 shares. Blackrock Ltd Liability Corporation owns 43,605 shares. Alliancebernstein Limited Partnership owns 22,900 shares or 0% of their US portfolio. Northern Trust Corp has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Vanguard Grp Incorporated stated it has 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). American Intll Grp Incorporated Incorporated accumulated 7,299 shares. Susquehanna Grp Limited Liability Partnership holds 0% or 23,127 shares. Meeder Asset holds 1,734 shares or 0% of its portfolio. Blackrock Institutional Tru Na reported 352,282 shares. Aqr Cap Mgmt Limited Liability Corp has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Mirati Therapeutics (NASDAQ:MRTX) Rating Reaffirmed

In a note revealed to clients on Friday morning, The Market Perform rating of Mirati Therapeutics (NASDAQ:MRTX) shares was maintained by Analysts at Leerink Swann, who now has a $9 PT on the stock. Leerink Swann’s PT suggests a possible downside of -19.64 % from the previous close of the company.

Investors sentiment decreased to 0.81 in Q4 2016. Its down 0.23, from 1.04 in 2016Q3. It turned negative, as 12 investors sold Mirati Therapeutics, Inc. shares while 19 reduced holdings. 7 funds opened positions while 18 raised stakes. 9.10 million shares or 3.41% less from 9.42 million shares in 2016Q3 were reported.

Jpmorgan Chase And holds 0% or 54,261 shares. Rhenman And Prtnrs Asset Mgmt Ab stated it has 0.05% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Baker Bros Advisors L P reported 2.27 million shares. Morgan Stanley owns 69,101 shares for 0% of their portfolio. Citigroup has 200 shares for 0% of their portfolio. Macquarie Group stated it has 80,000 shares. Blackrock Ltd Liability Corporation owns 43,605 shares. Alliancebernstein Limited Partnership owns 22,900 shares or 0% of their US portfolio. Northern Trust Corp has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Vanguard Grp Incorporated stated it has 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). American Intll Grp Incorporated Incorporated accumulated 7,299 shares. Susquehanna Grp Limited Liability Partnership holds 0% or 23,127 shares. Meeder Asset holds 1,734 shares or 0% of its portfolio. Blackrock Institutional Tru Na reported 352,282 shares. Aqr Cap Mgmt Limited Liability Corp has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Among 8 analysts covering Mirati Therapeutics (NASDAQ:MRTX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Mirati Therapeutics has $50 highest and $4.5000 lowest target. $21’s average target is 87.50% above currents $11.2 stock price. Mirati Therapeutics had 20 analyst reports since September 17, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, June 12 by Jefferies. The company was maintained on Friday, September 15 by Leerink Swann. Piper Jaffray downgraded Mirati Therapeutics, Inc. (NASDAQ:MRTX) rating on Thursday, September 17. Piper Jaffray has “Neutral” rating and $45 target. The firm has “Overweight” rating by Barclays Capital given on Monday, June 6. Wedbush maintained Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Tuesday, May 24 with “Outperform” rating. The firm earned “Hold” rating on Monday, July 17 by Jefferies. Leerink Swann maintained the stock with “Outperform” rating in Thursday, March 10 report. The firm earned “Hold” rating on Monday, June 6 by Jefferies. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Market Outperform” rating given on Friday, May 6 by Avondale. The rating was maintained by Jefferies on Monday, September 11 with “Hold”.

The stock increased 135.79% or $6.45 on September 15, reaching $11.2. About 48.77 million shares traded or 2686.86% up from the average. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has declined 76.51% since September 17, 2016 and is downtrending. It has underperformed by 93.21% the S&P500.

Analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report $-0.85 EPS on November, 2.They anticipate $0.12 EPS change or 12.37 % from last quarter’s $-0.97 EPS. After having $-0.74 EPS previously, Mirati Therapeutics, Inc.’s analysts see 14.86 % EPS growth.

More notable recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Prnewswire.com which released: “Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The …” on August 30, 2017, also Prnewswire.com with their article: “Mirati Therapeutics Reports First Quarter 2017 Financial Results” published on May 04, 2017, Prnewswire.com published: “Mirati Therapeutics Announces Closing of Public Offering of Common Stock and …” on January 11, 2017. More interesting news about Mirati Therapeutics, Inc. (NASDAQ:MRTX) were released by: Prnewswire.com and their article: “Mirati Therapeutics Announces Proposed Public Offering of Common Stock” published on January 05, 2017 as well as Seekingalpha.com‘s news article titled: “Mirati Pharma: What Differentiates It From The Pack?” with publication date: April 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.